Human disease
juvenile myelomonocytic leukemia
Mondo defines it as: “A myelodysplastic/myeloproliferative neoplasm of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages. Myelomonocytic proliferation is seen in the bone marrow and the blood. The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement. (WHO, 2001)”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 2299 | Leukaemia, chronic myelomonocytic | OMIA's OMIM numbers | 1 | Drug |
56.7
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| BCR | 0.08 | 17 |
| ABL1 | 0.08 | 11 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Glasdegib | None of these genes | Approved |
| Filgrastim | None of these genes | Phase 3 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Phase 2 |
| Ascorbic Acid | None of these genes | Phase 2 |
| Azacitidine | None of these genes | Phase 2 |
| Busulfan | None of these genes | Phase 2 |
| Carboplatin | None of these genes | Phase 2 |
| Cisplatin | None of these genes | Phase 2 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 2 |
| Cytarabine | None of these genes | Phase 2 |
| Daunorubicin | None of these genes | Phase 2 |
| Decitabine | None of these genes | Phase 2 |
| Dexamethasone | None of these genes | Phase 2 |
| Etanercept | None of these genes | Phase 2 |
| Etoposide | None of these genes | Phase 2 |
| Fludarabine | None of these genes | Phase 2 |
| Fludarabine Phosphate | None of these genes | Phase 2 |
| Gemcitabine | None of these genes | Phase 2 |
| Ifosfamide | None of these genes | Phase 2 |
| Imatinib | ABL1, BCR | Phase 2 |
| Isotretinoin | None of these genes | Phase 2 |
| Lenalidomide | None of these genes | Phase 2 |
| Melphalan | None of these genes | Phase 2 |
| Midostaurin | None of these genes | Phase 2 |
| Oxaliplatin | None of these genes | Phase 2 |
| Pomalidomide | None of these genes | Phase 2 |
| Rituximab | None of these genes | Phase 2 |
| Ruxolitinib | None of these genes | Phase 2 |
| Thiotepa | None of these genes | Phase 2 |
| Tipifarnib | None of these genes | Phase 2 |
| Trametinib | None of these genes | Phase 2 |
| Treosulfan | None of these genes | Phase 2 |
| Vorinostat | None of these genes | Phase 2 |
| Alemtuzumab | None of these genes | Phase 1/2 |
| Cedazuridine | None of these genes | Phase 1/2 |
| Methylprednisolone | None of these genes | Phase 1/2 |
| Mitoxantrone | None of these genes | Phase 1/2 |
| Tacrolimus Anhydrous | None of these genes | Phase 1/2 |
| Aldesleukin | None of these genes | Phase 1 |
| Clofarabine | None of these genes | Phase 1 |
| Gemtuzumab Ozogamicin | None of these genes | Phase 1 |
| H3b-8800 | None of these genes | Phase 1 |
| Ilorasertib | None of these genes | Phase 1 |
| Imetelstat | None of these genes | Phase 1 |
| Troculeucel | None of these genes | Phase 1 |
| Omacetaxine Mepesuccinate | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.